KAY E GERALD 4/A
4/A · INTEGRATED BIOPHARMA INC · Filed May 11, 2022
Insider Transaction Report
Form 4/AAmended
KAY E GERALD
DirectorCEO and President10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-05-06−100,000→ 150,000 totalExercise: $0.23Exp: 2024-05-24→ Common Stock (100,000 underlying) - Exercise/Conversion
Common Stock
2022-05-06$0.23/sh+100,000$23,000→ 5,345,889 total
Footnotes (3)
- [F1]This Form 4 is being amended to correct the Transaction Code in Table 1 and to include the previously inadvertently omitted disclosure in Table II.
- [F2]100,000 common stock shares acquired upon exercise of stock option grant dated May 24, 2019.
- [F3]The option vested 50% (125,000) on grant date (May 24, 2019) and in three equal annual installments for the remaining 50% (125,000) beginning on May 24, 2020 and ending May 24, 2022.